Key Considerations for Selection of ctDNA Detection Methods

Opinion
Video

Key opinion leaders evaluate the selection of available assays and platforms in relation to specific clinical objectives.

  1. How do you choose from the available assays/platforms based on your clinical objectives and desired information?
    • What criteria or considerations guide your selection?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
5 experts in this video
2 experts are featured in this series.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content
Neoantigen-Specific TIL/Pembrolizumab Elicit Responses in GI Cancers

Neoantigen-Specific TIL/Pembrolizumab Elicit Responses in GI Cancers

Tim Cortese
April 8th 2025
Article

A phase 2 study found that treatment with tumor-infiltrating lymphocytes elicited a partial response rate of 15.1% in patients with gastrointestinal cancers.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

Tim Cortese
March 31st 2025
Article

Muhammad Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer

Russ Conroy
March 31st 2025
Article

Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

Antitumor efficacy end points favored placebo over trilaciclib prior to FOLFOXIRI/bevacizumab in patients with untreated metastatic colorectal cancer.

Trilaciclib plus FOLFOXIRI/Bevacizumab Inhibits Myelosuppression in CRC

Roman Fabbricatore
March 3rd 2025
Article

Antitumor efficacy end points favored placebo over trilaciclib prior to FOLFOXIRI/bevacizumab in patients with untreated metastatic colorectal cancer.